Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,740,785.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $499.03, for a total value of $4,740,785.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $161,906,790.29. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Price Performance

Shares of UTHR stock opened at $497.11 on Friday. The stock’s 50-day moving average is $520.91 and its 200 day moving average is $540.30. United Therapeutics Corporation has a 1-year low of $396.12 and a 1-year high of $609.35. The company has a market cap of $21.32 billion, a P/E ratio of 17.79, a PEG ratio of 2.51 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same period in the prior year, the firm posted $6.41 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis. On average, analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on UTHR. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Morgan Stanley set a $515.00 target price on United Therapeutics in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Arjuna Capital lifted its stake in shares of United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after buying an additional 18 shares during the period. Sage Rhino Capital LLC lifted its position in United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC lifted its position in United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 24 shares during the period. Meeder Advisory Services Inc. grew its stake in United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 26 shares during the last quarter. Finally, Independent Advisor Alliance grew its stake in United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 27 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.